EP. 1: Updates in the Diagnosis and Management of HER2-Mutant NSCLC
February 27th 2025
On January 30, 2025, a group of thoracic oncologists gathered for an in-person workshop to discuss advances in diagnosing and treating non–small cell lung cancer (NSCLC) related to an HER2 mutation. The session was moderated by Joshua Sabari, MD; and Benjamin Levy, MD. As they focused on HER2 biomarker testing, treatment sequencing, and emerging therapies (including antibody-drug conjugates [ADCs] and TKIs), the faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.
